Panel Discussion: Supply Chain Resiliency for Indian Healthcare & Pharma

Indian pharmaceutical industry is the third largest in the world by volume. India exported pharmaceutical products worth 24.6 billion USD in FY22. India is import dependent for few Key starting materials (KSM), drug intermediates (DI) and Active Pharmaceutical Ingredients (API). Imports of pharmaceutical products accounted for ~9.5 bln USD for FY22 with high reliance on China. To reduce import dependence, the government has implemented various schemes to attract large investments in the healthcare and pharma sector. Hence there is increased focus on domestic sourcing of raw material.
• Identification and management of healthcare & pharma supply chain risks
• Government push: What next after PLI schemes to catapult India as global mfg. destination
• Healthcare & Pharma compliance checks & controls: Focus on supply chain
• Supplier onboarding: Assessment of new and existing suppliers or channel partners for financial and non-financial parameters
Moderator: Ms. Sudeepta Veerapaneni, Supply Chain & Network Operations Practice, Deloitte
Panelist:
Mr. Arun Kumar, Vice President & Head SCM, Metro Chem API Private Limited
Mr. P V Raju, Senior Vice President Supply Chain, Biological E Limited
Mr. Ram Kumar, Global Head - Manufacturing Science Technology Group (MSTG) OSD & Sterile, Cipla
Mr. Abhirup Das, Chief Operating Officer, Oren